Download the eBook to learn how the use of CAR technology is advancing the treatment of cancer and transforming patient treatment.
The use of chimeric antigen receptor (CAR) technology is making significant advances in the treatment of certain types of cancer and is transforming the way we think about patient treatment. As with many new technologies, progress is being made to overcome hurdles and streamline the manufacturing of these therapies.
In this eBook, we delve further into the cell therapy workflow and highlight the patient as a focal point throughout this journey. We also explore how a GMP-compliant, semiautomated manufacturing platform can result in consistent, efficacious CAR T cell production.
Contents include:
- From vendor to cell therapy partner: an interview with Xavier de Mollerat du Jeu, Thermo Fisher Scientific
- Application Note: Autologous CAR T cell manufacturing using a semiautomatic, closed, modular workflow
- Infoposter: Cell therapy workflow: integrated solutions from collection to delivery
- Articles:
- Raw material considerations for cell therapy manufacturing
- Cell therapy vendor qualification process
- Improved harmonization of critical characterization assays across cell therapies
- Development of a closed and automated bioreactor technology for cell therapy manufacturing – a sharing of our journey